Biochemical techniques confirm the presence of 1,4-dihydropyridine and D-600 inhibitable calcium channels in skeletal muscle, supporting previous electrophysiological findings.
Answers are grounded in this paper and cite their sources.
Biochemical support for Ca channels in skeletal muscle; confirms prior electrophysiological data but leaves open clinical translation.
Saturable binding sites for the labelled calcium antagonist (+/-)[3H]nimodipine were found in guinea-pig hind limb skeletal muscle homogenates. Binding sites were enriched in a microsomal pellet by differential centrifugation of the homogenate. [3H]Nimodipine binding (Kd = 1.5 +/- 0.03 nM, Bmax = 2.1 +/- 0.25 pmol/protein, at 37 degrees C) copurified (6-fold) in this fraction with [3H]ouabain binding (6.6-fold) and 125I-alpha-bungarotoxin binding (5-fold). d-cis-Diltiazem (but not 1-cis-diltiazem) stimulated (+/-) [3H]nimodipine binding (ED50 1 microM) by increasing the Bmax. Binding sites discriminated between the optical enantiomers of 1.4-dihydropyridine calcium antagonists and the optically pure enantiomers of D-600. The data confirm, with biochemical techniques, the presence of 1,4-dihydropyridine and (+/-) D-600 inhibitable calcium channels in skeletal muscle, previously found with electrophysiological techniques.
No takes yet. Share an insight, caveat, or question.
Ferry et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: